Molecular mechanisms of cisplatin resistance

Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer

Slamon, D. J., Godolphin, W. J., Jones, L. A., Holt, J. A., Wong, S., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J. A., Ullrich, A., et al. (1989) · Science · doi:10.1126/science.2470152 · Cited by 6,817

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., & Helleday, T. (2005) · Nature · doi:10.1038/nature03443 · Cited by 5,198

The resurgence of platinum-based cancer chemotherapy

Kèlland, L. R. (2007) · Nature reviews. Cancer · doi:10.1038/nrc2167 · Cited by 4,733

Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer

de Gramont, A., Figer, A., Seymour, M., Homerin, M., Hmissi, A., Cassidy, J., Boni, C., Cortes-Funes, H., Cervantes, A., Freyer, G., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.16.2938 · Cited by 3,815

Mitochondrial membrane permeabilization in cell death

Kroemer, G., Galluzzi, L., & Brenner, C. (2007) · Physiological Reviews · doi:10.1152/physrev.00013.2006 · Cited by 3,598

Autophagy and the Integrated Stress Response

Kroemer, G., Mariño, G., & Levine, B. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.09.023 · Cited by 3,506

Cisplatin: mode of cytotoxic action and molecular basis of resistance

Siddik, Z. H. (2003) · Oncogene · doi:10.1038/sj.onc.1206933 · Cited by 3,335

Molecular Mechanisms of Mammalian DNA Repair and the DNA Damage Checkpoints

Sancar, A., Lindsey-Boltz, L. A., Ünsal-Kaçmaz, K., & Linn, S. (2004) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.73.011303.073723 · Cited by 3,317

Calreticulin exposure dictates the immunogenicity of cancer cell death

Obeid, M., Tesniere, A., Ghiringhelli, F., Fimia, G. M., Apetoh, L., Perfettini, J.-L., Castedo, M., Mignot, G., Panaretakis, T., Casares, N., et al. (2007) · Nature Medicine · doi:10.1038/nm1523 · Cited by 3,216

Structure, Recognition, and Processing of Cisplatin−DNA Adducts

Jamieson, E. R., & Lippard, S. J. (1999) · Chemical Reviews · doi:10.1021/cr980421n · Cited by 2,953

Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer

Armstrong, D. K., Bundy, B. N., Wenzel, L. B., Huang, H. Q., Baergen, R. N., Lele, S., Copeland, L. J., Walker, J. L., & Burger, R. A. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052985 · Cited by 2,626

p53 in health and disease

Vousden, K. H., & Lane, D. P. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2147 · Cited by 2,351

A Randomized Controlled Trial of Fluorouracil Plus Leucovorin, Irinotecan, and Oxaliplatin Combinations in Patients With Previously Untreated Metastatic Colorectal Cancer

Goldberg, R. M., Sargent, D. J., Morton, R. F., Fuchs, C. S., Ramanathan, R. K., Williamson, S. K., Findlay, B., Pitot, H. C., & Alberts, S. R. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2004.09.046 · Cited by 2,251

EGF–ERBB signalling: towards the systems level

Citri, A., & Yarden, Y. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1962 · Cited by 2,056

A family of drug transporters: the multidrug resistance-associated proteins

Borst, P., Evers, R., Kool, M., & Wijnholds, J. (2000) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/92.16.1295 · Cited by 1,751

DNA Repair by ERCC1 in Non–Small-Cell Lung Cancer and Cisplatin-Based Adjuvant Chemotherapy

Olaussen, K. A., Dunant, A., Fouret, P. J., Brambilla, E. M., André, F., Haddad, V., Clermont, E., Filipits, M., Pirker, R., Popper, H., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060570 · Cited by 1,725

Cancer Susceptibility and the Functions of BRCA1 and BRCA2

Venkitaraman, A. R. (2002) · Cell · doi:10.1016/s0092-8674(02)00615-3 · Cited by 1,713

Phase III Multicenter Randomized Trial of Oxaliplatin Added to Chronomodulated Fluorouracil–Leucovorin as First-Line Treatment of Metastatic Colorectal Cancer

Giacchetti, S., Perpoint, B., Zidani, R., Bail, N. L., Faggiuolo, R., Focan, C., Chollet, P. J. M., Llory, J., Letourneau, Y., Coudert, B. P., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.1.136 · Cited by 1,404

DNA MISMATCH REPAIR

Kunkel, T. A., & Erie, D. A. (2005) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.74.082803.133243 · Cited by 1,372

The ATM–Chk2 and ATR–Chk1 Pathways in DNA Damage Signaling and Cancer

Smith, J., Tho, L. M., Xu, N., & Gillespie, D. A. (2010) · Advances in cancer research · doi:10.1016/b978-0-12-380888-2.00003-0 · Cited by 1,331

Immunogenic death of colon cancer cells treated with oxaliplatin

Tesnière, A., Schlemmer, F., Boige, V., Kepp, O., Martins, I., Ghiringhelli, F., Aymeric, L., Michaud, M., Apétoh, L., Barault, L., et al. (2009) · Oncogene · doi:10.1038/onc.2009.356 · Cited by 1,224

Cytoplasmic localization of p21Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells

Zhou, B. P., Liao, Y., Xia, W., Spohn, B., Lee, M., & Hung, M. (2001) · Nature Cell Biology · doi:10.1038/35060032 · Cited by 1,148

Post‐translational modifications and activation of p53 by genotoxic stresses

Appella, E., & Anderson, C. W. (2001) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.2001.02225.x · Cited by 1,095

ATR-Mediated Checkpoint Pathways Regulate Phosphorylation and Activation of Human Chk1

Zhao, H., & Piwnica-Worms, H. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.13.4129-4139.2001 · Cited by 1,091

Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers

Sakai, W., Swisher, E. M., Karlan, B. Y., Agarwal, M. K., Higgins, J., Friedman, C., Villegas, E., Jacquemont, C., Farrugia, D. J., Couch, F. J., et al. (2008) · Nature · doi:10.1038/nature06633 · Cited by 1,086

Resistance to therapy caused by intragenic deletion in BRCA2

Edwards, S. L., Brough, R., Lord, C. J., Natrajan, R., Vatcheva, R., Levine, D. A., Boyd, J., Reis-Filho, J. S., & Ashworth, A. (2008) · Nature · doi:10.1038/nature06548 · Cited by 1,011

Survivin, cancer networks and pathway-directed drug discovery

Altieri, D. C. (2007) · Nature reviews. Cancer · doi:10.1038/nrc2293 · Cited by 1,000

The human homologs of checkpoint kinases Chk1 and Cds1 (Chk2) phosphorylate p53 at multiple DNA damage-inducible sites.

Shieh, S.-Y., Ahn, J., Tamai, K., Taya, Y., & Prives, C. (2000) · Genes & Development · doi:10.1101/gad.14.3.289 · Cited by 972

BRCA1 and BRCA2: 1994 and beyond

Narod, S. A., & Foulkes, W. D. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1431 · Cited by 967

Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals

Ishida, S., Lee, J., Thiele, D. J., & Herskowitz, I. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.162491399 · Cited by 927

Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents.

O'Connor, P. M., Jackman, J., Bae, I., Myers, T. G., Fan, S., Mutoh, M., Scudiero, D. A., Monks, A., Sausville, E. A., Weinstein, J. N., et al. (1997) · PubMed · Cited by 867

Mitotic catastrophe: a mechanism for avoiding genomic instability

Vitale, I., Galluzzi, L., Castedo, M., & Kroemer, G. (2011) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3115 · Cited by 834

Clinical development of platinum complexes in cancer therapy: an historical perspective and an update

Lebwohl, D., & Canetta, R. M. (1998) · European Journal of Cancer · doi:10.1016/s0959-8049(98)00224-x · Cited by 756

Requirement for ERK Activation in Cisplatin-induced Apoptosis

Wang, X., Martindale, J. L., & Holbrook, N. J. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m004583200 · Cited by 678

Drug Resistance and ATP-Dependent Conjugate Transport Mediated by the Apical Multidrug Resistance Protein, MRP2, Permanently Expressed in Human and Canine Cells

Cui, Y., König, J., Buchholz, U., Spring, H., Leier, I., & KEPPLER, D. O. R. (1999) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)23190-4 · Cited by 674

The ATP-dependent glutathione S-conjugate export pump

Ishikawa, T. (1992) · Trends in Biochemical Sciences · doi:10.1016/0968-0004(92)90489-v · Cited by 658

Superiority of Oxaliplatin and Fluorouracil-Leucovorin Compared With Either Therapy Alone in Patients With Progressive Colorectal Cancer After Irinotecan and Fluorouracil-Leucovorin: Interim Results of a Phase III Trial

Rothenberg, M. L., Oza, A. M., Bigelow, R., Berlin, J. D., Marshall, J. L., Ramanathan, R. K., Hart, L. L., Gupta, S., Garay, C. A., Burger, B., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.11.126 · Cited by 646

Molecular Mechanisms of Mammalian Global Genome Nucleotide Excision Repair

Gillet, L. C. J., & Schärer, O. D. (2006) · Chemical Reviews · doi:10.1021/cr040483f · Cited by 642 · cited 1×

Interactions of Antitumor Metallodrugs with Serum Proteins: Advances in Characterization Using Modern Analytical Methodology

Timerbaev, A. R., Hartinger, C. G., Aleksenko, S. S., & Keppler, B. K. (2006) · Chemical Reviews · doi:10.1021/cr040704h · Cited by 615

Cisplatin: From DNA damage to cancer chemotherapy

Cohen, S. M., & Lippard, S. J. (2001) · Progress in nucleic acid research and molecular biology · doi:10.1016/s0079-6603(01)67026-0 · Cited by 614

ERCC1 and Thymidylate Synthase mRNA Levels Predict Survival for Colorectal Cancer Patients Receiving Combination Oxaliplatin and Fluorouracil Chemotherapy

Shirota, Y., Stoehlmacher, J., Brabender, J., Xiong, Y.-P., Uetake, H., Danenberg, K. D., Groshen, S. G., Tsao-Wei, D. D., Danenberg, P. V., & Lenz, H. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.23.4298 · Cited by 611

Overexpression of Metallothionein Confers Resistance to Anticancer Drugs

Kelley, S. L., Basu, A., Teicher, B. A., Hacker, M. P., Hamer, D. H., & Lazo, J. S. (1988) · Science · doi:10.1126/science.3175622 · Cited by 601

Is Cisplatin-Induced Cell Death Always Produced by Apoptosis?

González, V. M., Fuertes, M. A., Alonso‐Moreno, C., & Pérez, J. M. (2001) · Molecular Pharmacology · doi:10.1124/mol.59.4.657 · Cited by 579

Xeroderma Pigmentosum Group F Caused by a Defect in a Structure-Specific DNA Repair Endonuclease

Sijbers, A. M., de Laat, W. L., Ariza, R. R., Biggerstaff, M., Wei, Y.-F., Moggs, J. G., Carter, K. C., Shell, B. K., Evans, E. L., de Jong, M. C., et al. (1996) · Cell · doi:10.1016/s0092-8674(00)80155-5 · Cited by 546

The formation, isolation and characterization of DNA adducts produced by anticancer platinum complexes

Eastman, A. R. (1987) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(87)90009-x · Cited by 542

Cisplatin Induces Endoplasmic Reticulum Stress and Nucleus-independent Apoptotic Signaling

Mandic, A., Hansson, J., Linder, S. T., & Shoshan, M. C. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210284200 · Cited by 507

ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy.

Metzger, R., Leichman, C. G., Danenberg, K. D., Danenberg, P. V., Lenz, H.-J., Hayashi, K., Groshen, S. G., Salonga, D. S., Cohen, H., Laine, L., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.1.309 · Cited by 505

Loss of DNA mismatch repair in acquired resistance to cisplatin.

Aebi, S. P., Kurdi-Haidar, B., Gordon, R. T., Cenni, B., Zheng, H., Fink, D. A., Christen, R. D., Boland, C. R., Koi, M., Fishel, R. A., et al. (1996) · PubMed · Cited by 502

The Structure-Specific Endonuclease Ercc1-Xpf Is Required To Resolve DNA Interstrand Cross-Link-Induced Double-Strand Breaks

Niedernhofer, L. J., Odijk, H., Budzowska, M., van Drunen, E., Maas, A., Theil, A. F., de Wit, J., Jaspers, N. G. J., Beverloo, H. B., Hoeijmakers, J. H. J., et al. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.13.5776-5787.2004 · Cited by 493

The role of DNA mismatch repair in drug resistance

Nebel, S. (1998) · ETH Zürich Research Collection · doi:10.3929/ethz-a-001915508 · Cited by 461

Restoration of the immunogenicity of cisplatin-induced cancer cell death by endoplasmic reticulum stress

Martins, I., Kepp, O., Schlemmer, F., Adjemian, S., Tailler, M., Shen, S., Michaud, M., Menger, L., Gdoura, A., Tajeddine, N., et al. (2010) · Oncogene · doi:10.1038/onc.2010.500 · Cited by 443

The role of DNA mismatch repair in drug resistance.

Fink, D. A., Aebi, S. P., & Howell, S. B. (1998) · PubMed · Cited by 410

Cisplatin (cis-diamminedichloroplatinum II)

Prestayko, A. W., D'Aoust, J. C., Issell, B. F., & Crooke, S. T. (1979) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(79)80057-2 · Cited by 405

Survivin: A new target for anti-cancer therapy

Ryan, B. M., O’Donovan, N., & Duffy, M. J. (2009) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2009.05.003 · Cited by 378

Sustained Activation of JNK/p38 MAPK Pathways in Response to Cisplatin Leads to Fas Ligand Induction and Cell Death in Ovarian Carcinoma Cells

Mansouri, A., Ridgway, L. D., Korapati, A. L., Zhang, Q. C., Tian, L., Wang, Y., Siddik, Z. H., Mills, G. B., & Claret, F. X. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m208134200 · Cited by 377

Medical Treatment of Advanced Testicular Cancer

Feldman, D. R. (2008) · JAMA · doi:10.1001/jama.299.6.672 · Cited by 374

Clinical Perspectives on Platinum Resistance

Giaccone, G. (2000) · Drugs · doi:10.2165/00003495-200059004-00002 · Cited by 364

Cisplatin resistance: Preclinical findings and clinical implications

Köberle, B., Tomicic, M. T., Usanova, S., & Kaina, B. (2010) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2010.07.004 · Cited by 361

Increased Expression of the Copper Efflux Transporter ATP7A Mediates Resistance to Cisplatin, Carboplatin, and Oxaliplatin in Ovarian Cancer Cells

Samimi, G., Safaei, R., Katano, K., Holzer, A. K., Rochdi, M., Tomioka, M., Goodman, M., & Howell, S. B. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0137 · Cited by 357

Transcription-coupled nucleotide excision repair as a determinant of cisplatin sensitivity of human cells.

Furuta, T., Ueda, T., Aune, G. J., Sarasin, A. R., Kraemer, K. H., & Pommier, Y. G. (2002) · PubMed · Cited by 349

Contribution of the Major Copper Influx Transporter CTR1 to the Cellular Accumulation of Cisplatin, Carboplatin, and Oxaliplatin

Holzer, A. K., Manorek, G., & Howell, S. B. (2006) · Molecular Pharmacology · doi:10.1124/mol.106.022624 · Cited by 323

Effect of BRCA1/2 Mutations on Long-Term Survival of Patients With Invasive Ovarian Cancer: The National Israeli Study of Ovarian Cancer

Chetrit, A., Hirsh‐Yechezkel, G., Ben‐David, Y., Lubin, F., Friedman, E., & Sadetzki, S. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.6905 · Cited by 323

Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy

Joaquim Bellmunt, B., Paz-Ares, L. G., Cuello, M., Cecere, F. L., Albiol, S., Guillém, V., Gallardo, E., Carles, J., Méndez, P., de la Cruz, J. J., et al. (2007) · Annals of Oncology · doi:10.1093/annonc/mdl435 · Cited by 319

Novobiocin and Additional Inhibitors of the Hsp90 C-Terminal Nucleotide- binding Pocket

Donnelly, A. C., & Blagg, B. S. J. (2008) · Current Medicinal Chemistry · doi:10.2174/092986708786242895 · Cited by 316

ERCC1-XPF Endonuclease Facilitates DNA Double-Strand Break Repair

Ahmad, A., Robinson, A. R., Duensing, A. U., van Drunen, E., Beverloo, H. B., Weisberg, D. B., Hasty, P., Hoeijmakers, J. H. J., & Niedernhofer, L. J. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.00293-08 · Cited by 315

ATR-Chk2 Signaling in p53 Activation and DNA Damage Response during Cisplatin-induced Apoptosis

Pabla, N., Huang, S., Mi, Q.-S., Daniel, R., & Dong, Z. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m707568200 · Cited by 309

ERCC1 and ERCC2 Expression in Malignant Tissues From Ovarian Cancer Patients

Dabholkar, M., Bostick-Bruton, F., Weber, C., Bohr, V. A., Egwuagu, C. E., & Reed, E. (1992) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/84.19.1512 · Cited by 305

Molecular determinants of immunogenic cell death elicited by anticancer chemotherapy

Kepp, O., Galluzzi, L., Martins, I., Schlemmer, F., Adjemian, S., Michaud, M., Sukkurwala, A. Q., Menger, L., Zitvogel, L., & Kroemer, G. (2011) · Cancer and Metastasis Reviews · doi:10.1007/s10555-011-9273-4 · Cited by 303

Tumor-suppressor p53: implications for tumor development and prognosis.

Kirsch, D. G., & Kastan, M. B. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.9.3158 · Cited by 299

Cisplatin and Adriamycin Resistance Are Associated with MutLα and Mismatch Repair Deficiency in an Ovarian Tumor Cell Line

Drummond, J. T., Anthoney, A., Brown, R. E., & Modrich, P. L. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.33.19645 · Cited by 295

The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance: correlation with replicative bypass of platinum-DNA adducts.

Vaisman, A., Varchenko, M., Umar, A., Kunkel, T. A., Risinger, J. I., Barrett, J. C., Hamilton, T. C., & Chaney, S. G. (1998) · PubMed · Cited by 294

Effect of Extracellular Signal-regulated Kinase on p53 Accumulation in Response to Cisplatin

Persons, D. L., Yazlovitskaya, E. M., & Pelling, J. C. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m004267200 · Cited by 293

DNA unwinding produced by site-specific intrastrand crosslinks of the antitumor drug cis-diamminedichloroplatinum(II)

Bellon, S. F., Coleman, J. H., & Lippard, S. J. (1991) · Biochemistry · doi:10.1021/bi00246a021 · Cited by 293

Acquisition of resistance to cisplatin is accompanied by changes in the cellular pharmacology of copper.

Katano, K., Kondo, A., Safaei, R., Holzer, A. K., Samimi, G., Mishima, M., Kuo, Y., Rochdi, M., & Howell, S. B. (2002) · PubMed · Cited by 290

Enhancing Tumor-Specific Uptake of the Anticancer Drug Cisplatin with a Copper Chelator

Ishida, S., McCormick, F. P., Smith‐McCune, K., & Hanahan, D. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.04.011 · Cited by 290

Current Development of Clinical Inhibitors of Poly(ADP-Ribose) Polymerase in Oncology

Ratnam, K., & Low, J. A. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2260 · Cited by 290

Eukaryotic nucleotide excision repair: from understanding mechanisms to influencing biology

Shuck, S. C., Short, E. A., & Turchi, J. J. (2008) · Cell Research · doi:10.1038/cr.2008.2 · Cited by 289

Two-polymerase mechanisms dictate error-free and error-prone translesion DNA synthesis in mammals

Shachar, S., Ziv, O., Avkin, S., Adar, S., Wittschieben, J., Reißner, T., Chaney, S., Friedberg, E. C., Wang, Z., Carell, T., et al. (2009) · The EMBO Journal · doi:10.1038/emboj.2008.281 · Cited by 284

Role of Glutathione in the Regulation of Cisplatin Resistance in Cancer Chemotherapy

Chen, H. H. W., & Kuo, M. T. (2010) · Metal-Based Drugs · doi:10.1155/2010/430939 · Cited by 284

Preclinical Perspectives on Platinum Resistance

Kèlland, L. R. (2000) · Drugs · doi:10.2165/00003495-200059004-00001 · Cited by 280

DNA Repair: Enzymatic Mechanisms and Relevance to Drug Response

Chaney, S. G., & Sancar, A. (1996) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/88.19.1346 · Cited by 279

Cisplatin Preferentially Binds Mitochondrial DNA and Voltage-Dependent Anion Channel Protein in the Mitochondrial Membrane of Head and Neck Squamous Cell Carcinoma: Possible Role in Apoptosis

Yang, Z., Schumaker, L. M., Egorin, M. J., Zuhowski, E. G., Guo, Z., & Cullen, K. J. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1037 · Cited by 270

The Acquisition of hMLH1 Methylation in Plasma DNA after Chemotherapy Predicts Poor Survival for Ovarian Cancer Patients

Gifford, G., Paul, J., Vasey, P. A., Kaye, S. B., & Brown, R. E. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0732 · Cited by 262

Preclinical studies identifying carboplatin as a viable cisplatin alternative

Harrap, K. R. (1985) · Cancer Treatment Reviews · doi:10.1016/0305-7372(85)90015-5 · Cited by 259

Adriamycin cardiomyopathy—risk factors

Minow, R. A., Benjamin, R. S., Lee, E. T., & Gottlieb, J. A. (1977) · Cancer · doi:10.1002/1097-0142(197704)39:4 · Cited by 252

A canalicular multispecific organic anion transporter (cMOAT) antisense cDNA enhances drug sensitivity in human hepatic cancer cells.

Koike, K., Kawabe, T., Tanaka, T., Toh, S., Uchiumi, T., Wada, M., Akiyama, S. I., Ono, M., & Kuwano, M. (1997) · PubMed · Cited by 249

hMLH1 expression and cellular responses of ovarian tumour cells to treatment with cytotoxic anticancer agents

Brown, R. E., Hirst, G. L., Gallagher, W. M., McIlwrath, A. J., Margison, G. P., van der Zee, A. G., & Anthoney, A. (1997) · Oncogene · doi:10.1038/sj.onc.1201167 · Cited by 243

Antitumor activity of 1,2-diaminocyclohexaneplatinum complexes against Sarcoma-180 ascites form

Kidani, Y., Kenji Inagaki, Z., Iigo, M., Hoshi, A., & Kuretani, K. (1978) · Journal of Medicinal Chemistry · doi:10.1021/jm00210a029 · Cited by 239

Metallothionein content correlates with the sensitivity of human small cell lung cancer cell lines to cisplatin

Division, P. (1992) · Lung Cancer · doi:10.1016/0169-5002(92)90185-m · Cited by 238

Apoptosis regulation in tetraploid cancer cells

Castedo, M., Coquelle, A., Vivet, S., Vitale, I., Kauffmann, A., Dessen, P., Péquignot, M. O., Casares, N., Valent, A., Mouhamad, S., et al. (2006) · The EMBO Journal · doi:10.1038/sj.emboj.7601127 · Cited by 224

Effect of BRCA mutations on the length of survival in epithelial ovarian tumors.

David, Y. B., Chetrit, A., Hirsh-Yechezkel, G., Friedman, E., Beck, B. D., Beller, U., Ben-Baruch, G., Fishman, A., Levavi, H., Lubin, F., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.2.463 · Cited by 224

Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV): an orally active platinum drug.

Kèlland, L. R., Abel, G., McKeage, M. J., Jones, M., Goddard, P. M., Valenti, M., Murrer, B. A., & Harrap, K. R. (1993) · PubMed · Cited by 224

Recent Developments in the Field of Anticancer Platinum Complexes

Galanski, M. S. (2006) · Recent Patents on Anti-Cancer Drug Discovery · doi:10.2174/157489206777442287 · Cited by 223

Glutathione and glutathione-dependent enzymes in ovarian adenocarcinoma cell lines derived from a patient before and after the onset of drug resistance: intrinsic differences and cell cycle effects

Lewis, A. D., Hayes, J. D., & Wolf, C. R. (1988) · Carcinogenesis · doi:10.1093/carcin/9.7.1283 · Cited by 223

Acute apoptosis by cisplatin requires induction of reactive oxygen species but is not associated with damage to nuclear DNA

Berndtsson, M., Hägg, M., Panaretakis, T., Havelka, A. M., Shoshan, M. C., & Linder, S. T. (2006) · International Journal of Cancer · doi:10.1002/ijc.22132 · Cited by 221

Hierarchical involvement of Bak, VDAC1 and Bax in cisplatin-induced cell death

Tajeddine, N., Galluzzi, L., Kepp, O., Hangen, E., Morselli, E., Senovilla, L., Araujo, N., Pinna, G., Larochette, N., Zamzami, N., et al. (2008) · Oncogene · doi:10.1038/onc.2008.63 · Cited by 217

Activation of mitogen-activated protein kinases by cisplatin and their role in cisplatin-resistance

Brozović, A., & Osmak, M. (2006) · Cancer Letters · doi:10.1016/j.canlet.2006.10.007 · Cited by 204

Bypass of DNA Lesions Generated During Anticancer Treatment with Cisplatin by DNA Polymerase η

Alt, A., Lammens, K., Chiocchini, C., Lammens, A., Pieck, J. C., Kuch, D., Hopfner, K., & Carell, T. (2007) · Science · doi:10.1126/science.1148242 · Cited by 204

The mismatch-repair protein hMSH2 binds selectively to DNA adducts of the anticancer drug cisplatin

Mello, J. A., Acharya, S., Fishel, R. A., & Essigmann, J. M. (1996) · Chemistry & Biology · doi:10.1016/s1074-5521(96)90149-0 · Cited by 198

Increased Gene-Specific Repair of Cisplatin Interstrand Cross-Links in Cisplatin-Resistant Human Ovarian Cancer Cell Lines

Zhen, W. K., Link, C. J., O'Connor, P. M., Reed, E., Parker, R., Howell, S. B., & Bohr, V. A. (1992) · Molecular and Cellular Biology · doi:10.1128/mcb.12.9.3689 · Cited by 196

Nitrone spin traps and a nitroxide antioxidant inhibit a common pathway of thymocyte apoptosis

Slater, A. F. G., Nobel, S., Maellaro, E., Bustamante, J., Kimland, M., & Orrenius, S. (1995) · Biochemical Journal · doi:10.1042/bj3060771 · Cited by 188

Role of the Copper Transporter, CTR1, in Platinum-Induced Ototoxicity

More, S. S., Akil, O., Ianculescu, A. G., Geier, E. G., Lustig, L. R., & Giacomini, K. M. (2010) · Journal of Neuroscience · doi:10.1523/jneurosci.1544-10.2010 · Cited by 177

Expression of Bcl-xL in ovarian carcinoma is associated with chemoresistance and recurrent disease

Williams, J. A. S., Lucas, P. C., Griffith, K. A., Choi, M., Fogoros, S. K., Hu, Y., & Liu, J. R. (2004) · Gynecologic Oncology · doi:10.1016/j.ygyno.2004.10.026 · Cited by 173

Reduced drug accumulation as a major mechanism of acquired resistance to cisplatin in a human ovarian carcinoma cell line: circumvention studies using novel platinum (II) and (IV) ammine/amine complexes

Loh, S. Y., Mistry, P., Kèlland, L. R., Abel, G., & Harrap, K. R. (1992) · British Journal of Cancer · doi:10.1038/bjc.1992.419 · Cited by 167

Cisplatin sensitivity of testis tumour cells is due to deficiency in interstrand-crosslink repair and low ERCC1-XPF expression

Usanova, S., Piée‐Staffa, A., Sied, U., Thomale, J., Schneider, A., Kaina, B., & Köberle, B. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-248 · Cited by 164

Oxaliplatin for the treatment of cisplatin-resistant cancer: A systematic review

Stordal, B., Pavlakis, N., & Davey, R. (2007) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2007.01.009 · Cited by 163

Association between the level of ERCC-1 expression and the repair of cisplatin-induced DNA damage in human ovarian cancer cells.

Li, Q., Yu, J., Mu, C., Yunmbam, M. K., Slavsky, D., Cross, C. L., Bostick-Bruton, F., & Reed, E. (2000) · PubMed · Cited by 161

The structure‐specific endonuclease Ercc1—Xpf is required for targeted gene replacement in embryonic stem cells

Niedernhofer, L. J., Essers, J., Weeda, G., Beverloo, B., de Wit, J., Muijtjens, M., Odijk, H., Hoeijmakers, J. H. J., & Kanaar, R. (2001) · The EMBO Journal · doi:10.1093/emboj/20.22.6540 · Cited by 159

Mutations of the p53 gene do not occur in testis cancer.

Peng, H., Hogg, D., Malkin, D. M., Bailey, D., Gallie, B. L., Bulbul, M., Jewett, M. A. S., Buchanan, J., & Goss, P. E. (1993) · PubMed · Cited by 154

Altered ErbB Receptor Signaling and Gene Expression in Cisplatin-Resistant Ovarian Cancer

MacLeod, K. G., Mullen, P., Sewell, J. M., Rabiasz, G. J., Lawrie, S. S., Miller, E. P., Smyth, J. F., & Langdon, S. P. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-2684 · Cited by 152

ERCC1 expression as a predictive marker of squamous cell carcinoma of the head and neck treated with cisplatin-based concurrent chemoradiation

Jun, H. J., Ahn, M., Kim, H. S., Yi, S. Y., Han, J., Lee, S. K., Ahn, Y. C., Jeong, H.-S., Son, Y.-I., Baek, J.-H., et al. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604464 · Cited by 149

Bcl-2 Blocks Cisplatin-Induced Apoptosis and Predicts Poor Outcome Following Chemoradiation Treatment in Advanced Oropharyngeal Squamous Cell Carcinoma

Michaud, W. A., Nichols, A. C., Mroz, E. A., Faquin, W. C., Clark, J. R., Begum, S., Westra, W. H., Wada, H., Busse, P. M., Ellisen, L. W., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2581 · Cited by 147

Long‐term activation of SAPK/JNK, p38 kinase and fas‐L expression by cisplatin is attenuated in human carcinoma cells that acquired drug resistance

Brozović, A., Fritz, G., Christmann, M., Zisowsky, J., Jaehde, U., Osmak, M., & Kaina, B. (2004) · International Journal of Cancer · doi:10.1002/ijc.20522 · Cited by 146

Copper‐transporting P‐type adenosine triphosphatase (ATP7B) as a cisplatin based chemoresistance marker in ovarian carcinoma: Comparative analysis with expression of MDR1, MRP1, MRP2, LRP and BCRP

Nakayama, K., Kanzaki, A., Ogawa, K., Miyazaki, K., Neamati, N., & Takebayashi, Y. (2002) · International Journal of Cancer · doi:10.1002/ijc.10608 · Cited by 145

Altered expression and mutation of β‐catenin gene in gastric carcinomas and cell lines

Woo, D. K., Kim, H. S., Lee, H. S., Kang, Y. H., Yang, H. K., & Kim, W. H. (2001) · International Journal of Cancer · doi:10.1002/1097-0215(20010320)95:2 · Cited by 143

Cross-linking of glutathione to DNA by cancer chemotherapeutic platinum coordination complexes

Eastman, A. R. (1987) · Chemico-Biological Interactions · doi:10.1016/0009-2797(87)90004-4 · Cited by 141

A Novel Epidermal Growth Factor Receptor Inhibitor Promotes Apoptosis in Non–Small Cell Lung Cancer Cells Resistant to Erlotinib

de La Motte Rouge, T., Galluzzi, L., Olaussen, K. A., Zermati, Y., Tasdemir, E., Robert, T., Ripoche, H., Lazar, V., Dessen, P., Harper, F., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0538 · Cited by 141

The Internalization and Degradation of Human Copper Transporter 1 following Cisplatin Exposure

Holzer, A. K., & Howell, S. B. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1710 · Cited by 140

The phosphatidylinositol 3-kinase/AKT signal transduction pathway plays a critical role in the expression of p21WAF1/CIP1/SDI1 induced by cisplatin and paclitaxel.

Mitsuuchi, Y., Johnson, S. W., Selvakumaran, M., Williams, S. J., Hamilton, T. C., & Testa, J. R. (2000) · PubMed · Cited by 137

Increase of the resistance of human cervical carcinoma cells to cisplatin by inhibition of the MEK to ERK signaling pathway partly via enhancement of anticancer drug-induced NFκB activation

Yeh, P.-Y., Chuang, S., Yeh, K., Song, Y., Ea, C.-K., & Cheng, A. (2002) · Biochemical Pharmacology · doi:10.1016/s0006-2952(02)00908-5 · Cited by 136

Excision Repair Cross Complementation Group 1 Immunohistochemical Expression Predicts Objective Response and Cancer-Specific Survival in Patients Treated by Cisplatin-Based Induction Chemotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma

Handra‐Luca, A., Hernandez, J., Mountzios, G., Clermont, E., Guily, J. L. S., Soria, J., & Fouret, P. J. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0252 · Cited by 135

Loss of DNA Polymerase ζ Causes Chromosomal Instability in Mammalian Cells

Wittschieben, J. P., Reshmi, S. C., Gollin, S. M., & Wood, R. D. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2982 · Cited by 131

Role of multidrug resistance protein 2 (MRP2) in chemoresistance and clinical outcome in oesophageal squamous cell carcinoma

Yamasaki, M., Makino, T., Masuzawa, T., Kurokawa, Y., Miyata, H., Takiguchi, S., Nakajima, K., Fujiwara, Y., Matsuura, N., Mori, M., et al. (2011) · British Journal of Cancer · doi:10.1038/sj.bjc.6606071 · Cited by 130

p62/SQSTM1 involved in cisplatin resistance in human ovarian cancer cells by clearing ubiquitinated proteins

Yu, H., Su, J., Xu, Y., Kang, J., Li, H., Zhang, L., Yi, H., Xiang, X., Liu, F., & Sun, L. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.01.019 · Cited by 130

Overexpression of cMOAT (MRP2/ABCC2) Is Associated with Decreased Formation of Platinum-DNA Adducts and Decreased G2-Arrest in Melanoma Cells Resistant to Cisplatin

Liedert, B., Materna, V., Schadendorf, D., Thomale, J., & Lage, H. (2003) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.2003.12313.x · Cited by 129

Spontaneous development of drug resistance: mismatch repair and p53 defects in resistance to cisplatin in human tumor cells

Branch, P., Masson, M., Aquilina, G., Bignami, M., & Karran, P. (2000) · Oncogene · doi:10.1038/sj.onc.1203668 · Cited by 126

Effect of BRCA Mutations on the Length of Survival in Epithelial Ovarian Tumors

David, Y. B., Chetrit, A., Hirsh‐Yechezkel, G., Friedman, E., Beck, B. D., Beller, U., Ben‐Baruch, G., Fishman, A., Levavi, H., Lubin, F., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.2.463 · Cited by 126

Reversal of Multidrug Resistance by Natural Substances from Plants

Wang, Q., Michalak, K., Wesołowska, O., Deli, J., Molnár, P., Hohmann, J., Molnar, J. A., & Engi, H. (2010) · Current Topics in Medicinal Chemistry · doi:10.2174/156802610792928103 · Cited by 124

Overexpression of N-methylpurine-DNA glycosylase in Chinese hamster ovary cells renders them more sensitive to the production of chromosomal aberrations by methylating agents — a case of imbalanced DNA repair

Coquerelle, T. M., Dösch, J., & Kaina, B. (1995) · Mutation Research/DNA Repair · doi:10.1016/0921-8777(94)00035-5 · Cited by 123

Acquired Cisplatin Resistance in Human Lung Adenocarcinoma Cells Is Associated with Enhanced Autophagy

Ren, J., He, W., Nong, L., Zhu, Q., Hu, K., Zhang, R., Huang, L., Zhu, F., & Wu, G. (2010) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2009.0701 · Cited by 123

Cisplatin Induction of ERCC-1 mRNA Expression in A2780/CP70 Human Ovarian Cancer Cells

Li, Q., Gardner, K. L., Zhang, L., Tsang, B., Bostick-Bruton, F., & Reed, E. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.36.23419 · Cited by 120

The role of copper transporters in the development of resistance to Pt drugs

Safaei, R., Holzer, A. K., Katano, K., Samimi, G., & Howell, S. B. (2004) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2004.05.006 · Cited by 114

Prognostic Value of the Cu-Transporting ATPase in Ovarian Carcinoma Patients Receiving Cisplatin-Based Chemotherapy

Nakayama, K., Kanzaki, A., Terada, K., Mutoh, M., Ogawa, K., Sugiyama, T., Takenoshita, S., Itoh, K., Yaegashi, N., Miyazaki, K., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0454 · Cited by 114

In vitro platinum drug chemosensitivity of human cervical squamous cell carcinoma cell lines with intrinsic and acquired resistance to cisplatin

Mellish, K. J., Kelland, L., & Harrap, K. R. (1993) · British Journal of Cancer · doi:10.1038/bjc.1993.322 · Cited by 113

Analysis of gene expression profiles associated with cisplatin resistance in human ovarian cancer cell lines and tissues using cDNA microarray.

Sakamoto, M., Kondo, A., Kawasaki, K., Goto, T., Sakamoto, H., Miyake, K., Koyamatsu, Y., Akiya, T., Iwabuchi, H., Muroya, T., et al. (2001) · PubMed · Cited by 110

Mutagenic and carcinogenic properties of platinum-based anticancer drugs

Sanderson, B. J. S., Ferguson, L. R., & Denny, W. A. (1996) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/0027-5107(96)00022-x · Cited by 109

Contribution of c-erbB-2 and topoisomerase IIalpha to chemoresistance in ovarian cancer

Hengstler, J. G., Lange, J., Kett, A., Dornhöfer, N., Meinert, R., Arand, M., Knapstein, P. G., Becker, R., Oesch, F., & Tanner, B. (1999) · PubMed · doi:10.5167/uzh-113865 · Cited by 106

Down-regulation of Mammalian Sterile 20–Like Kinase 1 by Heat Shock Protein 70 Mediates Cisplatin Resistance in Prostate Cancer Cells

Ren, A., Yan, G., You, B., & Sun, J. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6248 · Cited by 106

MutS Homologue 2 and the Long-term Benefit of Adjuvant Chemotherapy in Lung Cancer

for the International Adjuvant Lung Trial-Bio investigators, Kamal, N. S., Soria, J., Mendiboure, J., Planchard, D., Olaussen, K. A., Rousseau, V., Popper, H., Pirker, R., Bertrand, P., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2204 · Cited by 103

P-glycoprotein expression is a marker for chemotherapy resistance and prognosis in advanced ovarian cancer.

Baekelandt, M. M. O., Holm, R., Nesland, J. M., Trope, C. G., & Kristensen, G. B. (2000) · PubMed · Cited by 102

Multidrug resistance-associated protein 2 determines the efficacy of cisplatin in patients with hepatocellular carcinoma

Wakai (2010) · Oncology Reports · doi:10.3892/or_00000721 · Cited by 99

Polymerase η mRNA Expression Predicts Survival of Non–Small Cell Lung Cancer Patients Treated with Platinum-Based Chemotherapy

Ceppi, P., Novello, S., Cambieri, A., Longo, M., Monica, V., Iacono, M. L., Levra, M. G., Saviozzi, S., Volante, M., Papotti, M. G., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1227 · Cited by 98

Cisplatinum and Taxol Induce Different Patterns of p53 Phosphorylation

Damia, G. L. M., Filiberti, L., Vikhanskaya, F., Carrassa, L., Taya, Y., D’Incalci, M., & Broggini, M. (2001) · Neoplasia · doi:10.1038/sj.neo.7900122 · Cited by 96

Mirk/Dyrk1B Maintains the Viability of Quiescent Pancreatic Cancer Cells by Reducing Levels of Reactive Oxygen Species

Deng, X., Ewton, D. Z., & Friedman, E. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2903 · Cited by 92

Phase II Study of Picoplatin As Second-Line Therapy for Patients With Small-Cell Lung Cancer

Eckardt, J. R., Bentsion, D., Lipatov, O. N., Polyakov, I. S., MacKintosh, F. R., Karlin, D. A., Baker, G. S., & Breitz, H. B. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.3235 · Cited by 92

Increased Incidence of Visceral Metastases in Scottish Patients With BRCA1/2-Defective Ovarian Cancer: An Extension of the Ovarian BRCAness Phenotype

Gourley, C., Michie, C. O., Roxburgh, P., Yap, T. A., Harden, S., Paul, J., Ragupathy, K., Todd, R., Petty, R., Reed, N., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.1082 · Cited by 88

Pharmacologic interruption of the mitogen-activated extracellular-regulated kinase/mitogen-activated protein kinase signal transduction pathway: potential role in promoting cytotoxic drug action.

Dent, P., & Grant, S. (2001) · PubMed · Cited by 88

Satraplatin: an orally available platinum analog for the treatment of cancer

Choy, H. (2006) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.6.7.973 · Cited by 85

Reactions of cisplatin hydrolytes with methionine, cysteine, and plasma ultrafiltrate studied by a combination of HPLC and NMR techniques

El-Khateeb, M., Appleton, T. G., Gahan, L. R., Charles, B. G., Berners‐Price, S. J., & Bolton, A.-M. (1999) · Journal of Inorganic Biochemistry · doi:10.1016/s0162-0134(99)00146-4 · Cited by 84

Mitochondrial Liaisons of p53

Galluzzi, L., Morselli, E., Kepp, O., Vitale, I., Pinti, M., & Kroemer, G. (2010) · Antioxidants and Redox Signaling · doi:10.1089/ars.2010.3504 · Cited by 83

Heat shock protein 27 was up-regulated in cisplatin resistant human ovarian tumor cell line and associated with the cisplatin resistance

Yamamoto, K., Okamoto, A., Isonishi, S., Ochiai, K., & Ohtake, Y. (2001) · Cancer Letters · doi:10.1016/s0304-3835(01)00532-8 · Cited by 81

Reversal of multidrug resistance of cancer through inhibition of P-glycoprotein by 5-bromotetrandrine

Jin, J., Wang, F., Wei, H., & Liu, G.-T. (2004) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-004-0868-0 · Cited by 80

Platinum speciation used for elucidating activation or inhibition of Pt-containing anti-cancer drugs

Michalke, B. (2010) · Journal of Trace Elements in Medicine and Biology · doi:10.1016/j.jtemb.2010.01.006 · Cited by 78

Inhibition of Chk1 Kills Tetraploid Tumor Cells through a p53-Dependent Pathway

Vitale, I., Galluzzi, L., Vivet, S., Nanty, L., Dessen, P., Senovilla, L., Olaussen, K. A., Lazar, V., Prudhomme, M., Golsteyn, R. M., et al. (2007) · PLoS ONE · doi:10.1371/journal.pone.0001337 · Cited by 77

Mirk/Dyrk1B in cancer

Friedman, E. (2007) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21451 · Cited by 77

Calpain activation through galectin-3 inhibition sensitizes prostate cancer cells to cisplatin treatment

Wang, Y., Nangia‐Makker, P., Balan, V., Hogan, V. A., & Raz, A. (2010) · Cell Death and Disease · doi:10.1038/cddis.2010.79 · Cited by 77

Molecular mechanisms of apoptosis and chemosensitivity to platinum and paclitaxel in ovarian cancer: biological data and clinical implications.

Gadducci, A., Cosio, S., Muraca, S., & Genazzani, A. R. (2002) · PubMed · Cited by 75

REV3L confers chemoresistance to cisplatin in human gliomas: The potential of its RNAi for synergistic therapy

Wang, H., Zhang, S., Wang, S., Lü, J., Wu, W., Weng, L., Chen, D., Zhang, Y., Lu, Z., Yang, H. J., et al. (2009) · Neuro-Oncology · doi:10.1215/15228517-2009-015 · Cited by 74

A cyclopalladated complex interacts with mitochondrial membrane thiol-groups and induces the apoptotic intrinsic pathway in murine and cisplatin-resistant human tumor cells

Serrano, F. A., Matsuo, A. L., Monteforte, P. T., Bechara, A. H. S., Smaili, S. S., Santana, D. P., Rodrigues, T., Pereira, F. V., Silva, L. S., Machado, J., et al. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-296 · Cited by 74

Expression of copper-transporting P-type adenosine triphosphatase (ATP7B) as a prognostic factor in human endometrial carcinoma

Aida, T., Takebayashi, Y., Shimizu, T., Okamura, C., Higasimoto, M., Kanzaki, A., Nakayama, K., Terada, K., Sugiyama, T., Miyazaki, K., et al. (2005) · Gynecologic Oncology · doi:10.1016/j.ygyno.2004.12.042 · Cited by 68

Loss of drug-induced activation of the CD95 apoptotic pathway in a cisplatin-resistant testicular germ cell tumor cell line

Spierings, D. C. J., de Vries, E. G. E., Vellenga, E., & de Jong, S. (2003) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4401248 · Cited by 67

Ovarian cancer: new clinical approaches

Ozols, R. F. (1991) · Cancer Treatment Reviews · doi:10.1016/0305-7372(91)90027-w · Cited by 66

Mirk/Dyrk1B, a novel therapeutic target, mediates cell survival in non-small cell lung cancer cells

Gao, J., Zheng, Z., Rawal, B., Schell, M. J., Bepler, G., & Haura, E. B. (2009) · Cancer Biology & Therapy · doi:10.4161/cbt.8.17.9322 · Cited by 65

DNA Damage Recognition and Nucleotide Excision Repair in Mammalian CellsPreprint

Wood, R. D., Araújo, S. J., Ariza, R. R., Batty, D. P., Biggerstaff, M., Evans, E. L., Gaillard, P.-H. L., Gunz, D., Köberle, B., Kuraoka, I., et al. (2000) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2000.65.173 · Cited by 65

Survivin as a predictor of cis‐diamminedichloroplatinum sensitivity in gastric cancer patients

Nakamura, M., Tsuji, N., Asanuma, K., Kobayashi, D., Yagihashi, A., Hirata, K., Torigoe, T., Sato, N., & Watanabe, N. (2004) · Cancer Science · doi:10.1111/j.1349-7006.2004.tb03169.x · Cited by 63

Heat Shock Protein 27 Protects L929 Cells from Cisplatin-Induced Apoptosis by Enhancing Akt Activation and Abating Suppression of Thioredoxin Reductase Activity

Zhang, Y., & Shen, X. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2090 · Cited by 60

Caspase-mediated cleavage of ATM during cisplatin-induced tubular cell apoptosis: inactivation of its kinase activity toward p53

Wang, J., Pabla, N., Wang, C., Wang, W., Schoenlein, P. V., & Dong, Z. (2006) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00509.2005 · Cited by 53

Elevated expression of TMEM205, a hypothetical membrane protein, is associated with cisplatin resistance

Shen, D., Ma, J., Okabe, M., Zhang, G., Xia, D., & Gottesman, M. M. (2010) · Journal of Cellular Physiology · doi:10.1002/jcp.22287 · Cited by 52

The Translesion Polymerase Rev3L in the Tolerance of Alkylating Anticancer Drugs

Roos, W. P., Tsaalbi‐Shtylik, A., Tsaryk, R., Güvercin, F., de Wind, N., & Kaina, B. (2009) · Molecular Pharmacology · doi:10.1124/mol.109.058131 · Cited by 52

c-Abl phosphorylation of ΔNp63α is critical for cell viability

Yuan, M., Luong, P., Hudson, C., Gudmundsdottir, K. K., & Basu, S. (2010) · Cell Death and Disease · doi:10.1038/cddis.2009.15 · Cited by 52

Effect of ERCC-1 overexpression on sensitivity of Chinese hamster ovary cells to DNA damaging agents.

Bramson, J. L., & Panasci, L. (1993) · PubMed · Cited by 51

Scytophycins, novel microfilament-depolymerizing agents which circumvent P-glycoprotein-mediated multidrug resistance.

Smith, C. D., Carmeli, S., MOORE, R. E., & Patterson, G. M. L. (1993) · PubMed · Cited by 50

The role of XAF1 in cancer.

Plenchette, S., Cheung, H. H., Fong, W. G., LaCasse, E. C., & Korneluk, R. G. (2007) · PubMed · Cited by 50

Death Receptor 5 and Bcl-2 Protein Expression as Predictors of Tumor Response to Gemcitabine and Cisplatin in Patients with Advanced Non-Small-Cell Lung Cancer

Han, J., Hong, E. K., Choi, B. G., Park, J. N., Kim, K. W., Kang, J., Jin, J., Park, S. Y., Hong, Y. S., & Lee, K. S. (2003) · Medical Oncology · doi:10.1385/mo:20:4:355 · Cited by 49

Patients with ERCC1-Negative Locally Advanced Esophageal Cancers May Benefit from Preoperative Chemoradiotherapy

Kim, M. K., Cho, K.-J., Kwon, G. Y., Park, S.-I., Kim, Y., Kim, J. H., Song, H.-Y., Shin, J. H., Jung, H., Lee, G. H., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4848 · Cited by 48

Frameshifts and deletions during in vitro translesion synthesis past Pt–DNA adducts by DNA polymerases β and η

Bassett, E., Vaisman, A., Leeman, K. T., McCall, C. M., Masutani, C., Hanaoka, F., & Chaney, S. G. (2002) · DNA repair · doi:10.1016/s1568-7864(02)00150-7 · Cited by 45

Oxaliplatin in First-line Therapy for Advanced Non–Small-Cell Lung Cancer

Raez, L. E., Kobina, S., & Santos, E. S. (2010) · Clinical Lung Cancer · doi:10.3816/clc.2010.n.003 · Cited by 42

Depleting Mirk Kinase Increases Cisplatin Toxicity in Ovarian Cancer Cells

Hu, J., & Friedman, E. (2010) · Genes & Cancer · doi:10.1177/1947601910377644 · Cited by 42

Changes in survivin messenger RNA level during cisplatin treatment in gastric cancer

Ikeguchi, M., & Kaibara, N. (2001) · International Journal of Molecular Medicine · doi:10.3892/ijmm.8.6.661 · Cited by 41

The Molecular Basis of Synergism between Carboplatin and ABT-737 Therapy Targeting Ovarian Carcinomas

Jain, H. V., & Meyer‐Hermann, M. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-3174 · Cited by 41

Mcl-1, Vascular Endothelial Growth Factor-R2, and 14-3-3σ Expression Might Predict Primary Response against Radiotherapy and Chemotherapy in Patients with Locally Advanced Squamous Cell Carcinomas of the Head and Neck

Erović, B. M., Pelzmann, M., Grasl, M. C., Johannes, P., Kornek, G. V., Brannath, W., Selzer, E., & Thurnher, D. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1170 · Cited by 39

Requirement for ERCC-1 and ERCC-3 gene products in DNA excision repair in vitro. Complementation using rodent and human cell extracts.

Biggerstaff, M., & Wood, R. D. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)50510-5 · Cited by 36

Predictors of response to chemo-radiotherapy and radiotherapy for esophageal squamous cell carcinoma.

Miyazaki, T., Kato, H., Faried, A., Sohda, M., Nakajima, M., Fukai, Y., Masuda, N., Manda, R., Fukuchi, M., Ojima, H., et al. (2005) · PubMed · Cited by 35

Mode of DNA binding of cis-platinum(II) antitumor drugs: a base sequence-dependent mechanism is proposed.

Kelman, A. D., & Peresie, H. J. (1980) · PubMed · Cited by 35

Resistance to caspase-8 and -9 fragments in a malignant pleural mesothelioma cell line with acquired cisplatin-resistance

Janson, V., Johansson, A. F., & Grankvist, K. (2010) · Cell Death and Disease · doi:10.1038/cddis.2010.54 · Cited by 34

p53 and HER2/neu Expression in Relation to Chemotherapy Response in Patients with Non-Small Cell Lung Cancer

Fijołek, J., Wiatr, E., Rowinska-Zakrzewska, E., Giedronowicz, D., Langfort, R., Chabowski, M., Orlowski, T. M., & Roszkowski, K. (2006) · The International Journal of Biological Markers · doi:10.1177/172460080602100203 · Cited by 33

Survivin antiapoptotic gene expression as a prognostic factor in non-small cell lung cancer: in situ hybridization study.

Karczmarek-Borowska, B., Filip, A. A., Wojcierowski, J., Smoleń, A., Pilecka, I., & Jabłonka, A. (2005) · PubMed · doi:10.5603/4604 · Cited by 32

Inhibitors of mTOR overcome drug resistance from topoisomerase II inhibitors in solid tumors

Gaur, S., Chen, L., Yang, L., Wu, X., Un, F., & Yen, Y. (2011) · Cancer Letters · doi:10.1016/j.canlet.2011.06.005 · Cited by 31

Biochemical pharmacology of homologous alicyclic mixed amine platinum(II) complexes in sensitive and resistant tumor cell lines.

Yoshida, M., Khokhar, A. R., & Siddik, Z. H. (1994) · PubMed · Cited by 26

Selectively induced high MRP gene expression in multidrug-resistant human HL60 leukemia cells

Wada, H., Saikawa, Y., Niida, Y., Nishimura, R., Noguchi, T., Matsukawa, H., Ichihara, T., & Koizumi, S. (1999) · Experimental Hematology · doi:10.1016/s0301-472x(98)00027-7 · Cited by 25

XAF1 mRNA expression improves progression-free and overall survival for patients with advanced bladder cancer treated with neoadjuvant chemotherapy

de Pinho, M. B., Costas, F., de Séllos, J., Dienstmann, R., Andrade, P. B., Herchenhorn, D., Peixoto, F. A., Santos, V. O., Small, I. A., Guimarães, D. P., et al. (2008) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2008.03.016 · Cited by 18

A new step ahead for the consideration of ERCC1 as a candidate biomarker to select NSCLC patients for the treatment of cetuximab in combination with cisplatin

Olaussen, K. A. (2009) · Cancer Biology & Therapy · doi:10.4161/cbt.8.20.9785 · Cited by 11

Molecular mechanisms of cell death: recommendations of the nomenclature committee on cell death 2018.

Galluzzi, L., Vitale, I., Aaronson, S. A., Abrams, J. M., Adam, D., Agostinis, P., Alnemri, E. S., Altucci, L., Amelio, I., Andrews, D. W., et al. (2018) · Cell Death & Differentiation · doi:10.1038/s41418-017-0012-4 · Cited by 6,680

Cisplatin: The first metal based anticancer drug

Ghosh, S. (2019) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2019.102925 · Cited by 1,816

Mitochondrial metabolism and cancer

Porporato, P. E., Filigheddu, N., Pedro, J. M. B., Kroemer, G., & Galluzzi, L. (2017) · Cell Research · doi:10.1038/cr.2017.155 · Cited by 1,323

The development of anticancer ruthenium( ii ) complexes: from single molecule compounds to nanomaterials

Zeng, L., Gupta, P., Chen, Y., Wang, E., Ji, L., Chao, H., & Chen, Z. (2017) · Chemical Society Reviews · doi:10.1039/c7cs00195a · Cited by 1,027

Platinum-based drugs: past, present and future

Dilruba, S., & Kalayda, G. V. (2016) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-016-2976-z · Cited by 909

Mechanisms of cisplatin resistance: DNA repair and cellular implications

Adams, M. N., Ashton, N. W., Paquet, N., O'Byrne, K. J., & Richard, D. J. (2014) · Cited by 7

Cisplatin: mode of cytotoxic action and molecular basis of resistance

Siddik, Z. H. (2003) · Oncogene · doi:10.1038/sj.onc.1206933 · Cited by 3,335

Systems biology of cisplatin resistance: past, present and future

Galluzzi, L., Vitale, I., Michels, J., Brenner, C., Szabadkai, G., Harel-Bellan, A., Castedo, M., & Kroemer, G. (2014) · Cell Death & Disease · doi:10.1038/cddis.2013.428 · Cited by 782

顺铂耐药的分子机制

Xi, Z., & Liu, Y. (2014) · Scientia Sinica Chimica · doi:10.1360/032013-305 · Cited by 4

Cisplatin and platinum drugs at the molecular level (Review)

Boulikas, T., & Vougiouka, M. (2003) · Oncology Reports · doi:10.3892/or.10.6.1663 · Cited by 730